



Geisinger Health Plan Policies and Procedure Manual

Policy: MP303

Section: Medical Benefit Policy

Subject: Genomic Analysis to Predict Thyroid Malignancy in FNA (Fine-Needle Aspiration)

Applicable Lines of Business

Commercial	X	CHIP	X
Medicare	X	ACA	X
Medicaid	X		

I. Policy: Genomic Analysis to Predict Thyroid Malignancy in FNA (Fine-Needle Aspiration)

II. Purpose/Objective:

To provide a policy of coverage regarding Genomic Analysis to Predict Thyroid Malignancy in FNA (Fine-Needle Aspiration)

III. Responsibility:

- A. Medical Directors
- B. Medical Management

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community.
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an illness, condition, injury or disability.

- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age

DESCRIPTION:

Gene expression analysis and mutation analysis has been developed as a means to identify benign nodules when cytopathology of thyroid fine needle aspirate is indeterminate, thereby reducing the number of unnecessary thyroid surgeries. The testing provides valuable additive information that may help guide decisions on the appropriate surgery.

INDICATIONS:

Thyroid FNA (Fine-Needle Aspiration) Analysis (e.g., Affirma, ThyraMIR, ThyroSeq, ThyGenX, etc) is considered medically necessary when the thyroid nodule is greater than or equal to 1.0 cm and fine needle aspiration is cytologically considered to be indeterminate (eg: Bethesda category III and IV), atypical, or suspicious for malignancy.

LIMITATIONS:

The use of a thyroid nodule gene expression classifier or mutation analysis is considered not medically necessary if criteria above is not met.

Medicaid Business Segment:

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis.

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in MP 15 - Experimental Investigational or Unproven Services or Treatment.

CODING ASSOCIATED WITH:

The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services. Please note that per Medicare coverage rules, only specific CPT/HCPCS Codes may be covered for the Medicare Business Segment. Please consult the CMS website at www.cms.gov or the local Medicare Administrative Carrier (MAC) for more information on Medicare coverage and coding requirements.

- 81210 BRAF, gene analysis V600 variant {Affirma malignancy classifier BRAF V600E testing}
- 81445 Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis, and RNA analysis when performed, 5-50 genes {ThyGenX}
- 81545 Oncology (thyroid), gene expression analysis of 142 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (eg, benign or suspicious) { Affirma Gene Expression Classifier}
- 81546 Oncology (thyroid), gene expression analysis of 10,196 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (eg, benign or suspicious) { Affirma Gene Expression Classifier}
- 0018U oncology (thyroid), microRNA profiling by RT-PCR of 10 microRNA sequences, utilizing fine needle aspirate, algorithm reported as a positive or negative result for moderate to high risk of malignancy {ThyraMIR}
- 0026U Oncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result ("Positive, high probability of malignancy" or "Negative, low probability of malignancy") {ThyroSeq}
- 81479 Unlisted molecular pathology procedure
- 0204U Oncology (thyroid), mRNA, gene expression analysis of 593 genes (including BRAF, RAS, RET, PAX8, and NTRK) for sequence variants and rearrangements, utilizing fine needle aspirate, reported as detected or not detected (Affirma Xpression Atlas)
- 0208U Oncology (medullary thyroid carcinoma), mRNA, gene expression analysis of 108 genes, utilizing fine needle aspirate, algorithm reported as positive or negative for medullary thyroid carcinoma (Affirma Medullary Thyroid Carcinoma (MTC) Classifier)
- 0245U Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis, and RNA analysis when performed, 5-50 genes {ThyGenX}
- 0287U Oncology (thyroid), DNA and mRNA, next-generation sequencing analysis of 112 genes, fine needle aspirate or formalin-fixed paraffin-embedded (FFPE) tissue, algorithmic prediction of cancer recurrence, reported as a categorical risk result (low, intermediate, high) { ThyroSeq}

0362U Oncology (papillary thyroid cancer), gene-expression profiling via targeted hybrid capture–enrichment RNA sequencing of 82 content genes and 10 housekeeping genes, formalin-fixed paraffin embedded (FFPE) tissue, algorithm reported as one of three molecular subtypes
Current Procedural Terminology (CPT®) © American Medical Association: Chicago, IL

LINE OF BUSINESS:

Eligibility and contract specific benefits, limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD's and NCD's will supercede this policy. For PA Medicaid Business segment, this policy applies as written.

REFERENCES:

- Labourier E, Shifrin A, et al. Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration Improves the Preoperative Diagnosis of Thyroid Nodules With Indeterminate Cytology. *JCEM* 2015;100 (7).
- Duick DS, Klopper JP, et al. The Impact of Benign Gene Expression Classifier Test Results on the Endocrinologist–Patient Decision to Operate on Patients with Thyroid Nodules with Indeterminate Fine-Needle Aspiration Cytopathology. *Thyroid*. 2012 Oct; 22(10): 996–1001
- Cibas ES, Baloch ZW, Fellegara G, et al. A prospective assessment defining the limitations of thyroid nodule pathologic evaluation. *Ann Intern Med*. 2013; 159(5):325-332
- Alexander EK, Schorr M, Klopper J, et al. Multicenter Clinical Experience with the Afirma Gene Expression Classifier. *J Clin Endocrinol Metab*. 2014; 99(1):119-125.
- Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. *N Engl J Med* 2012; 367(8):705-715
- Chudova D, Wilde JI, Wang ET, et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. *J Clin Endocrin Metab* 2010; 95(12):5296-5304
- Walsh PS, Wilde JI, Tom EY et al. Analytical performance verification of a molecular diagnostic for cytology-indeterminate thyroid nodules. *J Clin Endocrinol Metab* 2012; 97(12):E2297-306.
- Harrell RM, Bimston DN. Surgical Utility of Afirma: Effects of High Cancer Prevalence and Oncocytic Cell Types in Patients with Indeterminate Thyroid Cytology. *Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists* 2013:1-16
- Moses W, Weng J, Sansano I, et al. Molecular testing for somatic mutations improves accuracy of thyroid fine-needle aspiration biopsy. *World J Surg* 2010; 34(11):2589-2594
- Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". *Cancer Cytopathol* 2010; 118(1):17-23
- Cantara S, Capezzone M, Marchisotta S, et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. *J Clin Endocrinol Metab* 2010; 95(3):1365-1369
- Mathur A, Weng J, Moses W, et al. A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy. *Surgery* 2010; 148(6):1170-1177.
- Ferraz C, Eszlinger M, Paschke R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. *J Clin Endocrinol Metab* 2011; 96(7):2016-2026
- Nikiforova MN, Wald AI, Roy S, et al. Targeted Next-Generation Sequencing Panel (ThyroSeq) for Detection of Mutations in Thyroid Cancer. *J Clin Endocrinol Metab*. 2013; 98(11):E1852-1860.
- Angell, TE, Frates, MC, Medici, M, Liu, X, Kwong, N, Cibas, ES, Kim, MI, and Marqusee, E. Afirma benign thyroid nodules show similar growth to cytologically benign nodules during follow-up. *J Clin Endocrinol Metab*. 2015;100(11):E1477-E1483
- Brauner, E, Holmes, BJ, Krane, JF, Nishino, M, Zurakowski, D, Hennessey, JV, Faquin, WC, and Parangi, S. Performance of the Afirma gene expression classifier in Hurthle cell thyroid nodules differs from other indeterminate thyroid nodules. *Thyroid*. 2015;25(7):789-796

Marti, JL, Avadhani, V, Donatelli, LA, Niyogi, S, Wang, B, Wong, RJ, Shaha, AR, Ghossein, RA, Lin, O, Morris, LG, and Ho, AS. Wide inter-institutional variation in performance of a molecular classifier for indeterminate thyroid nodules. *Ann Surg Oncol*. 2015

Yang, SE, Sullivan, PS, Zhang, J, Govind, R, Levin, MR, Rao, JY, and Moatamed, NA. Has Afirma gene expression classifier testing refined the indeterminate thyroid category in cytology? *Cancer Cytopathol*. 2015

NCCN Clinical Practice Guidelines in Oncology™. © 2016 National Comprehensive Cancer Network, Inc. Thyroid cancer v4.2023

American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid*. 2009; 19(11):1167-1214

American Association of Clinical Endocrinologists and the American College of Endocrinology (AAACE/ACE) Position statement: Disease State Commentary: Molecular Diagnostic Testing of Thyroid Nodules with Indeterminate Cytopathology, 2014.

Santhanam P, Khthir R, Gress T, et al. Gene expression classifier for the diagnosis of indeterminate thyroid nodules: a meta-analysis. *Med Oncol*. 2016; 33(2):14.

Witt RL. Outcome of thyroid gene expression classifier testing in clinical practice. *Laryngoscope*. 2016; 126(2):524-527

Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid*. 2016; 26(1):1-133

Novitas Solutions, Inc. Local Coverage Determination (LCD): Biomarkers for Oncology (L35396) 07/26/18

Steward DL, Carty S, Sippel R, et al. Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study. *JAMA Oncol* doi:10.1001/jamaoncol.2018.4616.

Taye A, Gurciullo D, Miles BA, et al. Clinical performance of a next-generation sequencing assay (ThyroSeq v2) in the evaluation of indeterminate thyroid nodules. *Surgery* Jan 2018;163(1):97-103

Nikiforova MN, Mercurio S, Wald AI, et al. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. *Cancer* Apr 15 2018;124(8):1682-1690.

Lupo MA, Walts AE, Sistrunk JW, et al. Multiplatform molecular test performance in indeterminate thyroid nodules. *Diagn Cytopathol*. 2020; 48(12):1254-1264

Sistrunk JW, Shifrin A, Frager M, et al. Clinical performance of multiplatform mutation panel and microRNA risk classifier in indeterminate thyroid nodules. *J Am Soc Cytopathol*. 2020; 9(4):232-241

Vora A, Holt S, Haque W, Lingvay I. Long-term outcomes of thyroid nodule AFIRMA GEC testing and literature review: An institutional experience. *Otolaryngol Head Neck Surg*. 2020; 162(5):634-640.

Livhits MJ, Zhu CY, Kuo EJ, et al. Effectiveness of molecular testing techniques for diagnosis of indeterminate thyroid nodules: A randomized clinical trial. *JAMA Oncol*. 2021 Jan 1;7(1):70-77.

Liu JB, Ramonell KM, Carty SE, et al. Association of comprehensive thyroid cancer molecular profiling with tumor phenotype and cancer-specific outcomes. *Surgery*. 2023 Jan;173(1):252-259

Nasr CE, Andrioli M, Endo M, et al. Real-World Performance of the Afirma Genomic Sequencing Classifier (GSC)-A Meta-analysis. *J Clin Endocrinol Metab*. May 17 2023; 108(6): 1526-1532.

Kim NE, Raghunathan RS, Hughes EG, et al. Bethesda III and IV Thyroid Nodules Managed Nonoperatively after Molecular Testing with Afirma GSC or Thyroseq v3. *J Clin Endocrinol Metab*. Mar 30 2023

Kandil E, Metz TA, Issa PP, et al. Diagnostic Performance of Afirma and Interpace Diagnostics Genetic Testing in Indeterminate Thyroid Nodules: A Single Center Study. *Cancers* Mar 31 2023; 15(7).

This policy will be revised as necessary and reviewed no less than annually.

Devised: 1/4/2016

Revised: 1/24 (minor indication refinement)

Reviewed: 1/17, 1/18, 1/19, 1/20, 1/21, 1/22, 1/23,

CMS UM Oversight Committee Approval: 12/23

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.